The increasingly widespread emergence of obesity has become a matter of critical concern around the world due to its association with common morbidities including cancer, cardiovascular diseases and diabetes. Over-nutrition and the sedentary lifestyle are considered as the most significant causes of obesity: appropriate lifestyle and behavior interventions are the corner stones of successful weight loss, but to maintain such a lifestyle is highly challenging. There is therefore an urgent need to develop innovative non-or minimally-toxic means to combat obesity. Accordingly, ample natural products from plants (either as crude extracts or purified phytochemicals) have been scrutinized for their anti-obesogenic properties because they are believed to be non-toxic and costeffective, and frequently well-accepted by patients because of their traditional use. In this review, we will discuss adipose tissue and adipogenesis, signaling pathways involved in the regulation of adipogenesis, role of energy sensor protein of the body AMPK, and recently reported plant products in the management of obesity. We will provide a common platform for understanding obesity, and a possible mechanism of action for anti-obesogenic plant products through activated AMPK, which will be helpful in the scientific development of traditional herbal medicine.
main targets (mechanism of action) of these naturally occurring anti-obesogenic plant products and in particular the role of activated energy sensor protein '5 ' adenosine monophosphate-activated protein kinase' (AMPK) in the management of obesity will be discussed. But before heading towards those details it is vital to understand adipocytes and their differentiation process, adipogenesis.
Adipose Tissue and Adipogenesis
Adipose tissue is one of the most complex organs, containing adipocytes, immune cells, preadipocytes and fibroblasts; it secretes hormones (estrogen, leptin), adipokines and has regulatory roles in endocrine, immune and metabolic systems [15, 16] . Adipose tissue is critical for the homeostasis of energy and generally performs three different tasks. Firstly, it is the hub for the synthesis and storage of triglycerides. Secondly, in a situation of increased energy demands, the stored triglycerides are hydrolyzed, and the ensuing free fatty acids are then released into circulation.
Thirdly, it acts as endocrine organ, releasing adipokines [17] . Adipose tissue is widely considered as the main therapeutic target of many natural and synthetic anti-obesogenic products. Adipose tissue is divided into subcutaneous adipose tissue (SCAT) and visceral adipose tissue (VAT). Located centrally or subcutaneously, adipose tissue plays a key role in the survival of an individual because it is the main source of fatty acids for the production of heat and energy. Adipocytes or fat cells are the lipid-laden cells of adipose tissue that acquire the ability to accumulate lipids post differentiation (a process in which the cells from a common ancestor are derived mitotically and become different from one another in morphology and function). This differentiation of adipocytes is determined by the expression of genes which dictate the phenotype of adipocytes. The proteins involved in differentiation then direct the cells to perform their characteristic functions and are also critical for differentiation of pre-adipocytes into mature adipocytes [18] . Collectively, this process of preadipocytes differentiating into mature adipocytes is known as adipogenesis. Increase in the size (hypertrophy) and number (hyperplasia) of white adipose tissue (WAT) during adipogenesis (e.g. due to excessive energy intake accompanied by low energy expenditure) may lead to obesity [18, 19] .
During the process of adipogenesis, the multipotent mesenchymal stem cells (MSCs) are transformed into pre-adipocytes before undergoing secondary differentiation to become mature adipocytes which are laden with lipids and are responsive to insulin [20, 21] . Adipogenesis involves three well defined stages: commitment, determination and differentiation. These three stages can be summed up in four substages: (i) commitment of MSCs to adipocyte lineage and growth arrest of pre-adipocytes; (ii) determination of pre-adipocytes to proceed to next stage, involving replication of DNA and duplication of cell, commonly known as mitotic clonal expansion; (iii) early differentiation, involving expression of genes and transcriptional factors such as CCAAT/ enhancer binding proteins (C/EBPs) family and peroxisome proliferator activated receptor-γ (PPAR γ ); and (iv) late differentiation, involving significant increase in lipogenesis and induction of mostly lipogenic genes such as Fatty acid synthase (FAS), acetylo CoA carboxylase (ACC), adipose-specific fatty acid binding protein (aP2) [22] etc. The differentiation of MSCs into pre-adipocytes is also influenced by growth factors, hormones and insulin. During the progression of adipogenesis, mitotic clonal expansion of preadipocytes which are growth arrested will occur through repetitive rounds of mitotic divisions. Once the pre-adipocytes are released from the cell cycle, they gather cytoplasmic triglycerides and lose their fibroblastic morphology, while gaining the features of mature adipocytes. For successful transformation into mature adipocytes, the transformation of pre-adipocytes into a spherical shape is required, which is an indication of profound changes in the extracellular matrix (ECM), morphology of the cell and cytoskeletol components [22] . ECM provides strength, structural support, sites for the attachment of cell receptors, and acts as a source of cell signaling factors. In adipose tissue, ECM interconnects the adipocytes which results in the formation of cluster of fat cells in vitro and fat lobules in vivo [21] . ECM may also play a key role in modulating the differentiation of adipocytes. For instance, proteolytic degradation of the extracellular matrix of pre-adipocytes by cascade of plasminogen is essential for changes in the expression of adipocyte genes and deposition of fats [18, 23] . Recently, it has been revealed that events and changes (molecular and morphological) which are associated with the above-mentioned changes may modulate adipogensis directly, because they alter the expression of positive transcriptional regulators of adipogenesis such as C/EBPα and and brite adipose tissue in adults as well [35] . Although both brown and white adipocytes originate from MSCs, it is believed that the precursor cells giving rise to brown and white adipocytes are different ( Figure 1 ). MSCs are pledged either to adipogenic (Myf-5 negative) cells and give rise to white adipocytes or myogenic (Myf-5 positive) cells, giving rise to brown adipocytes [36, 37] . The Myf-negative precursor cells give rise to white pre-adipocytes through the expression of bone morphogenetic protein-2 and 4 (BMP 2 and 4). Similarly, the Myf-positive precursor cells give rise to brown pre-adipocytes through the expression of bone morphogenetic protein-7 (BMP 7) and trancriptional co-regulator PR-domain containing 16 (PRDM16) [36, 38] . The recent rediscovery of effective BAT in adult humans has invigorated interest in it as a viable and novel target for phytochemicals. Upregulating the proteins and transcriptional factors specifically expressed in brown or beige adipocytesis is a highly promising approach in the elimination of obesity. Activation of the thermogenic system in humans, either in WAT or BAT, should correlate well with an increase of energy expenditure. Interest in the prevention of obesity by regulation of non-shivering thermogenesis in BAT and brite adipose tissue through phytochemicals has been increasing rapidly due to their potential for side-effect-minimal medication. Various phytochemicals have been reported (Table 1) to induce browning of white adipose tissue, indicating their thermogenic effects. For example, genistein upregulates the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgc1α), Ucp1 and Sirt1 [39] . Similarly, Formononetin [40] and Myricetin [41] have also been reported to induce browning of white adipose tissue by upregulating the genes and transcriptional factors specifically expressed in BAT. 
4.Transcriptional Regulators of Adipogenesis
Adipogenesis requires the activation of several transcription factors including the CCAAT/ enhancer binding protein (C/EBP) family and peroxisome proliferator activated receptor-γ (PPARγ) [18] . Expression of the two members of C/EBP family (C/EBPβ and C/EBPδ) occurs at early stages of repressors of adipogenesis alter the activity and expression of PPARγ [52] . Transcriptional factors such as C/EBP β, C/EBP δ, kruppel like factor 5 (KLF5) and early β-cell factor 1 (EBF1) are known to directly induce the expression of PPARγ mRNA in adipogenesis [48] . Early β-cell factor 1 and 2 (EBF1 and EBF2) are induced during 3T3-L1 white pre-adipocytes differentiation but their pattern of expression is different [53] . EBF2 has been reported to regulate the expression of brown adipocyte adipogenesis [17, [55] [56] [57] . KLF2 directly inhibits the PPARγ promoter. Adenovirus-mediated ectopic expression of KLF2 has been shown to inhibit the expression of PPARγ, C/EBPα and SREBP-1c but did not have any effect on the expression of C/EBPβ and C/EBPδ [58] . KLF3 inhibits the differentiation of 3T3-L1 pre-adipocytes by repressing C/EBPα promoter [57] . Similarly, overexpression of KLF7 is reported to inhibit the differentiation of 3T3-L1 pre-adipocytes [59] . Over expression of KLF7 significantly decreases the expression of PPARγ, C/EBPα, adipsin and adipocyte protein-2 (aP2) [60] .
Globin transcription factors GATA2 and 3 are also reported to inhibit adipogenesis by down- 
Role of Signaling Pathways in Adipogenesis
MSCs are commited to either osteogenic or adipogenic lineages. This involves discrete signaling pathways including Wnt (canonical and non-canonical), Bone morphogenetic protein (BMP) and
Hedgehog signaling pathways. These pathways have very strong influences on the central regulators of both osteogenesis (Runx2) and adipogenesis (PPARγ), two factors which are responsible for the differentiation of MSCs into either osteocytes or adipocytes and work antagonistically with overexpression of one factor repressing the other [63, 64] .
Bone Morphogenetic Proteins and Transforming Growth Factors-β Pathway
Bone morphogenetic proteins (BMPs) belong to the superfamily of transforming growth factors-β (TGF-β) and have been identified as regulators of osteogenesis and adipogenesis [63, 65] . BMPs are involved in the differentiation of disparate cell types including adipocytes. Initially, BMPs were thought to have a key role only in the formation of bone, but their role in all other organs has been discovered recently [66] . BMPs are known for their regulatory roles in various cellular process including proliferation, apoptosis, differentiation, and determination of cell fate in adulthood and during embryogenesis [65] [66] [67] . BMPs play different roles in the differentiation of adipocytes depending on the stage of cells and BMP type and dosage [68] . BMP-2 in particular, inhibits adipogenesis and promotes osteogenic differentiation in bone marrow stromal cells [69] BMP-7 has been reported to induce the differentiation of brown adipocytes [70] . 3T3-F44 2A pre-adipocytes treated with BMP-2 showed a decrease in insulin-induced lipid accumulation [71] , but BMP-7
enhanced the differentiation of 3T3-L1 pre-adipocytes, demonstrating the contradictory roles of BMPs in adipogenesis [72, 73] . Similarly, BMP-4 regulates the commitment of precursor cells into white adipogenic lineage [74] . BMP-4 and BMP-7 can also activate development of beige adipocytes in human precursor cells [75] . Overexpression of BMP-4 in transgenic mice showed a reduction in the mass and size of white adipose tissue (WAT), and induced browning of WAT (known as britening) [76] . Induced expression of BMP-4 upregulated the expression of key regulators of brown adipose tissue, peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α) and its target gene, UCP1 [77, 78] . 
Hedgehog Signaling Pathway
The Hedgehog (Hh) signaling pathway is involved in the development of both vertebrates and invertebrates [80] . It is known to be one of the important modulators of the stem cell differentiation process and its role in the differentiation of MSCs had been demonstrated in several studies [81, 82] .
This signaling pathway is downregulated during the differentiation of human adipocytes, and upon activation it reduces the expression of key adipogenic transcription factor C/EBPα and hinders 
Wnt Signaling Pathway
Wnts (Wingless-type MMTV integration site family members) are secreted glycoproteins that work both in an autocrine manner and a paracrine manner [65] . Wnt signaling pathways are a group of conserved signal transduction pathways and consist of proteins which convey signals through cell surface receptors into the cell. These pathways are involved in processes including cell differentiation and proliferation in adult tissue regeneration, and in embryonic development [65] . These signal transduction pathways can be divided into canonical (β-catenin dependent) and non-canonical (β-catenin independent) pathway. Wnt proteins control the proliferation of cell, cell fate, behaviour and survival by exerting signals through these canonical and non-canonical pathways. MSCs are differentiated into osteocytes and myocytes instead of adipocytes upon activation of Wnt/β-catenin signaling pathway. Conversely, interruption of Wnt/β-catenin signaling promotes the differentiation of pre-adipocytes into mature adipocytes [84] . One important component of the Wnt/β-catenin pathway, Wnt10b, had been reported to be responsible for the anti-adipogenic function of canonical pathway. Wnt10b is highly expressed in pre-adipocytes but its expression declines promptly after induction of differentiation [85] . Its overexpression stabilizes cytoplasmic β-catenin and block adipogenesis in 3T3-L1 pre-adipocytes [86, 87] . Moreover, the Wnt/β-catenin signaling pathway also inhibits brown adipogenesis by disrupting the induction of PPARγ and C/EBPα. Wnt10a and (FABP 4) promoter had been shown to reduce total body fat by 50% and provide resistance to WAT accumulation in high fat diets, as well as blocking the development of BAT [89] . These findings had led to the conclusion that the activation of the Wnt/β-catenin signaling pathway during the process of adipogenesis may be a key strategy for anti-obesogenic drugs. For example, 6-gingerol (found in ginger) had been reported to have anti-adipogenic effects, inhibiting adipogenic differentiation through activation of Wnt/β-catenin signaling pathway [90] . Similarly, toosendanin (a triterpenoid)
has been reported recently to inhibit adipogenesis through Wnt/β-catenin dependent pathway [91] .
Thus, there is a need to investigate further other bioactive compounds and their mechanism of action in inhibiting adipogenesis through Wnt/β-catenin signaling pathway
Besides the canonical pathway, members of Wnt family also activate the non-canonical β-catenin independent pathway. Activation of non-canonical pathway through Wnt5a is reported to antagonize the canonical pathway, promoting the differentiation of pre-adipocytes into mature adipocytes [92] .
AMPK; Central Target of Many Natural and Synthetic Compounds
5'-Adenosine monophosphate-activated protein kinase (AMPK), is a serine/threonine kinase.
The heterotrimeric protein consists of 3 subunits: catalytic subunit α which consists of further two subunits α1, α2 and regulatory subunits β and γ consisting of two subunits (β1, β2) and three subunits (γ1, γ2, γ3) respectively [93, 94] . Being expressed in different kind of tissues (liver, adipose, skeletal, kidney and hypothalamus), [95] AMPK plays a central role in controlling and regulating cell cycle and cellular energy homeostasis; it is therefore the most widely studied protein in the investigation and discovery of natural as well as pharmacological compounds against weight loss. ACC1 converts acetyl-coA to malonyl co-A and hence catalyzes the rate limiting step in the synthesis of FAs [98, 99] . Moreover, AMPK inhibits synthesis of cholesterol by phosphorylating and inhibiting HMG-CoA-reductase [98] . It is also known for its inhibitory effects on the mammalian target of rapamycin (mTOR) which is the fundamental cell growth regulator and is highly conserved in all eukaryotes. AMPK remains active under poor energy and nutrient conditions while mTOR remains inactive in such conditions [100] . Thus, the inhibiting effects of AMPK on mTOR define antigrowth and antiproliferative activities under stress conditions. AMPK may therefore play a central role in the inhibition of adipogenesis by inhibiting the mTOR signaling pathway. In the case of obesity, AMPK remains inactive due to the availability of excess nutrients and energy sources, therefore an external stimulus is needed to activate AMPK. Much effort has been spent attempting to delineate the exogenous activators of AMPK, and the debate is still ongoing. The net effect of AMPK activation is an increase in body's cellular energy level [95] . Lipid/glucose homeostasis, mitochondrial biogenesis, food intake and insulin signaling are some of the important functions of AMPK.
Metabolic Functions of AMPK and Role in Adipogenesis
Therefore, the protein is a key therapeutic target for the treatment of major metabolic disorders including obesity and type-2 diabetes [101] . pre-adipocytes, highlighting the potential role of AMPK in the inhibition of adipogenesis [109] In addition, AMPK has also been shown to be pertinent in the britening of WAT thereby increasing the energy expenditure through thermogenesis [110, 111] . It has also been reported that the activity of AMPK increases during the differentiation of brown adipocytes and that targeting AMPK by short interfering RNAs (siRNAs), inhibits the differentiation of pre-adipocytes into mature brown adipocytes [16, 112] . These studies clearly indicate AMPK as a potential therapeutic target in the prevention and treatment of many metabolic diseases including obesity.
AMPK Activation by Upstream Kinases
AMPK is broadly known as a fuel-sensing enzyme -it is involved in sensitivity to, and the homeostasis of lipids, glucose and insulin [113] . Under different physiological conditions, the subunits of AMPK behave and are regulated differentially. Activation of AMPK can be achieved by either through upstream kinases or allosterically through AMP [95] . It is activated when there is increase in the consumption of adenosine triphosphate (ATP) which leads to an increase in the ratio of adenosine monophosphate (AMP) to ATP [114] . The best studied mechanisms of the activation of AMPK are allosteric activation by binding of either AMP or ADP at γ subunit and by phosphorylation of the α subunit [114] . Conditions including hypoxia, exercise, ischaemia and hypoglycaemia usually alter the cellular adenine nucleotides levels (suppress ATP consumption) and subsequently enhance the activity of AMPK [115] . of AMPK in adipocytes [121] . Therefore, further study about activation of AMPK by anti-obesogenic products through upstream kinases is required to understand their mechanism of action and develop new anti-obesogenic products specifically targeting these kinases to treat adiposity.
Exogenous Activators of AMPK
In recent years, much effort had been made to delineate the pathways of AMPK, and to identify the enzymes acetyl-CoA carboxylase and FAS [123] . AICAR has also been known to cause arrest of cell cycle at the G1 phase by inducing activation of p53 followed by activation of the cell cycle inhibitor protein p21 [124] , stopping the growth and proliferation of cell cycle under stress conditions.
Although AICAR has promising effects as mentioned above, since it mimics the effects of AMP, it has also other AMPK-independent effects [122] . For instance, it regulates other AMP-regulated enzymes such as fructose-1,6-bisphosphatase (FBPase) and stimulates muscle glycogen phosphorylase [122, 125] . In addition, due to short half-life and poor bioavailability, it is unlikely to be used in the treatment of metabolic syndrome and Type-2 diabetes [126] and these are considered to be the main obstacles in the development of AICAR as a promising drug [122] . mechanism for the activation of AMPK [129] . Salicylate is among the oldest drugs used by humans.
It is a phytochemical, produced naturally and obtained from willow bark [126] but for medicinal purposes, it is now used in acetylated form (Aspirin) [127] . Aspirin is easier to take orally than salicylate, and upon entering the blood stream, it is rapidly broken down to salicylate [94] . of AMPK, LKB1 [127] . Thiazolidinediones (TZDs) are insulin-sensitizing drugs and consist of rosiglitazone, pioglitazone and troglizatone [126] ; these compounds indirectly activate AMPK and promote phosphorylation of ACC in various types of tissues including adipose, skeletal muscles and liver [126, 132] . They enhance the accumulation of AMP by inhibiting the complex I of the mitochondrial respiratory chain and hence activate AMPK indirectly [133] . Moreover, they enhance the expression of PPARγ which in turn increases the expression and release of adiponectin from adipocytes [132] , activates AMPK in liver and skeletal muscle, increases the oxidation of fatty acids and uptake of glucose, and decreases the production of hepatic glucose [94] .
Indirect activation of AMPK by phytochemicals had also been demonstrated in numerous studies. Quercetin is one of the most abundant flavonoids found in many plants, food and grains, and is known to activate AMPK indirectly [104] . Exposure of 3T3-L1 cells to quercetin resulted in a decrease expression of positive regulators of adipogenesis and attenuation of adipogenesis. This was due to the phosphorylation of AMPK and its downstream substrate ACC [104] . Another indirect activator of AMPK that can be found in grapes is resveratrol. Resveratrol activates AMPK indirectly by increasing AMP:ATP ratio through inhibition of mitochondrial ATP production [105, 122, 134] .
Treatment with resveratrol has been shown to stimulate mitochondrial biogenesis, glucose uptake and reduce accumulation of lipids in different types of cells [126, [135] [136] [137] . In addition, Curcumin derived from Curcuma longa activates AMPK by phosphorylating its α subunit. Exposure of 3T3-L1
adipocytes to curcumin enhanced the phosphorylation and activation of AMPK and decreased the expression of ACC by phosphorylation [138] . 
Anti-Obesogenic Effects of Plant Products and Their Mechanism of Action
It is evident from the literature that down-or upregulation of hundreds of transcriptional factors, hormones, and enzymes may induce obesity. Accordingly, there is no single mechanism of action of the various phytochemicals/plant products tested in the management of obesity. Different kinds of plant products have different types of mechanisms (Table 2) . Their mechanism of action may include: 1. Inhibition of Pancreatic Lipase (PL) Activity. PL is a crucial enzyme for the hydrolysis of triglycerides into monoglycerides and fatty acids. It hydrolyses 50-70 % of the total dietry fat [142] and the inhibition of this enzyme is among approaches used to combat obesity. The mechanism involves inhibition of absorption of triglycerides in the bodies. PL inhibition is being widely studied Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 July 2019 doi:10.20944/preprints201907.0040.v1
to evaluate the potential of natural products to inhibit dietary fat absorption [143] [144] [145] . 2. Increase in Energy Expenditure. As mentioned above, brown adipose tissues transform energy from stored fat into heat (thermogenesis). UCP1 is the central activator of thermogenic effect and induction of its expression by natural anti-obesogenic plant products is one route to reduce obesity [7, 146] . obesogenic products may prove fruitful in the development of anti-obesity therapies [7, 151] . 
Summary and Outlook
Obesity is a common disorder caused by the interaction of environmental, genetic and nutritional factors, and its pervasiveness is accelerating worldwide. Changes in lifestyle, extensive consumption of calorific foods, and increasingly sedentary lifestyles are the predominant causative factors for this rise in obesity. Returning to healthy lifestyles, for example daily exercise and consumption of food rich in minerals and fibres is the surest route to successful weight loss, but for many it is extremely challenging to maintain. For decades, synthetic chemicals had been explored to fill this need. Despite generating positive results, they have also caused adverse effects that muted their benefits. Traditionally used medicinal plants which contain a wide range of natural chemicals have been used for the treatment of many infectious as well as chronic disorders including obesity.
These natural products from plants (phytochemicals) may play a supportive role in combating obesity by helping obese people to lose weight. A synergestic activity could be conferred by the combination of multiple natural products to increase their anti-obesogenic activities and mode of action on multiple targets, which may prove to be advantageous over other chemical treatments.
Anti-obesogenic studies either based on in vitro studies or mouse models do not guarantee the same results in humans, and so clinical trials must be performed to evaluate the effectiveness of bioactive compounds in order to understand their safety, bioavailability, pharmacokinetics and efficacy.
Clinical trials should be planned carefully to evaluate both immediate and long-term side effects of 
